Accepted for Publication: December 6, 2012.
Published Online: May 13, 2013. doi:10.1001/jamaneurol.2013.2077
Study concept and design: Angus-Leppan, Rudge, and Mead.
Acquisition of data: Angus-Leppan, Rudge, Mead, and Vincent.
Analysis and interpretation of data: Angus-Leppan, Collinge, and Vincent.
Drafting of the manuscript: Angus-Leppan, Rudge, and Collinge.
Critical revision of the manuscript for important intellectual content: All authors.
Administrative, technical, and material support: Angus-Leppan, Rudge, and Mead.
Study supervision: Rudge, Mead, and Collinge.
Conflict of Interest Disclosures: Dr Collinge is a director and shareholder of D-Gen Limited, an academic spin-out company working in the field of prion disease diagnosis, decontamination, and therapeutics. D-Gen markets the ICSM35 antibody used in this study. Dr Vincent and the University of Oxford hold patents and receive royalties and payments for antibody assays.
Additional Contributions: We thank the patient’s family, who encouraged us to publish this case report. We are grateful to the Oxford National Institute for Health Research Biomedical Research Centre for support, to Drs M. Woodhall and L. Jacobson for the antibody tests, and to Prof Sebastian Brandner for the histological studies.